About Careers MedBlog Contact us

Combination Therapy Shown as Effective for Higher-Risk DS/AML Patients

by Himabindu Venkatakrishnan on December 22, 2014 at 5:29 PM
Font : A-A+

 Combination Therapy Shown as Effective for Higher-Risk DS/AML Patients

Patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia may find that combination of drugs azacitidine and lenalidomide as an effective frontline treatment regimen. A phase two study that investigated the potential of the drugs azacitidine (AZA) and lenalidomide (LEN), demonstrated this.

Myelodysplastic syndrome (MDS) is a type of cancer in which the bone marrow does not make enough healthy blood cells, resulting in abnormal (blast) cells in the blood and/or bone marrow. Higher-risk patients experience an unusually large percentage of blasts in their blood. Patients often develop infections, anemia, or excessive bleeding. Acute myeloid leukemia (AML) is a blood cell cancer and is the most common acute leukemia affecting adults, with incidences increasing with age.


The study, led by Guillermo Garcia-Manero, M.D., professor of leukemia at The University of Texas MD Anderson Cancer Center, shed new light on effective dosage schedule and amounts for the drugs, something previously unknown. The combination therapy was well tolerated in the study of 88 patients.

The study results were presented today by Courtney Dinardo, M.D., assistant professor of leukemia, at the 56th Annual Meeting of the American Society of Hematology (ASH) annual conference in San Francisco and were published in the Dec. 5 issue of the ASH journal Blood.

"Hypomethylating (HMA) agents such as AZA and LEN are currently the front line of therapeutic choice for patients with higher-risk MDS, and also frequently employed in elderly AML patients not otherwise eligible for standard intensive therapy," said DiNardo. "A number of combination strategies are under development to improve the results of HMA therapy. Given what we know about the effectiveness of AZA and LEN in patients with MDS and AML, a scientific rationale existed to explore this therapeutic combination strategy."

DiNardo's team evaluated the administration of AZA and LEN on days 6 to 10 of a 28-day cycle of treatment. The combination therapy appeared to be effective in patients presenting with as high as 30 percent blasts or abnormal blood/bone marrow cells.

"The responses were rapid with a median of two cycles for the drugs to be effective. Treatment with this dosage and schedule was well tolerated," said DiNardo.

Members of DiNardo's study team included Naval Daver, M.D., Eliza Jabbour, M.D., Tapan Kadia, M.D., Gautam Borthakur, M.D., Marina Konopleva, M.D., Ph.D., Naveen Pemmaraju, M.D., Hui Yang, M.D., Ph.D., Yue Wei, William Wierda, M.D., Ph.D., Jorge Cortes, M.D., Farhad Ravandi, M.D., Hagop Kantarjian, M.D., and Guillermo Garcia-Manero, M.D., all of the department of leukemia; and Carlos Bueso-Ramos, M.D, Ph.D., and Keyur Patel, M.D., Ph.D., department of hematopathology.

The study was funded by the National Institutes of Health (P30 CA016672), Celgene Corporation, the Edward P. Evans Foundation, and Fundación Ramón Areces.

Source: Newswise


Recommended Reading

Latest General Health News

 People Living Close to the Seaside Enjoy Better Health
Direct coastal access may represent a viable route to public health promotion, but the relationships of coastal living are not strongest among lower-income groups.
 Over Four Million Gardeners Place Their Hearing in Danger
New research by Tinnitus UK has found that over four million gardeners are putting their hearing capacity at risk this summer without using safety protection.
Breaking the Barrier: Unraveling Mucus Plugs to Save Lives in COPD
Mucus plugs could be targeted to help reduce fatalities from chronic obstructive pulmonary disease.
 Disease Modifying Therapies for Multiple Sclerosis Continue to Drive Up Healthcare Cost
The development of reliable curative therapies for multiple sclerosis could significantly reduce the economic burden of the disease on patients and wider society.
 New Genetic Variant Provides Protection Against Alzheimer's Disease
A genetic variant in a patient protected from autosomal dominant Alzheimer's disease (ADAD) suggests a role for RELN signaling in resilience to dementia.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Combination Therapy Shown as Effective for Higher-Risk DS/AML Patients Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests